Methylphenidate increases the motor effects of L-dopa in Parkinson's disease: A pilot study

Clinical Neuropharmacology

Volumn 24, Issue 4, 2001, Pages 208-213

  Camicioli, Richard ^a,b   Lea, Eric ^a   Nutt, John G ^a   Sexton, Gary ^a   Oken, Barry S ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Dopamine transporter; L Dopa; Methylphendidate; Parkinson's disease; Pharmacodynamics

Indexed keywords

CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; LEVODOPA; METHYLPHENIDATE; PLACEBO; PRAMIPEXOLE; ROPINIROLE;

ADULT; AGED; ANXIETY; AROUSAL; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG POTENTIATION; DYSKINESIA; HUMAN; MOOD; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REACTION TIME;

AGED; ANALYSIS OF VARIANCE; COGNITION; DOPAMINE AGENTS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; METHYLPHENIDATE; MIDDLE AGED; MOTOR SKILLS; PARKINSON DISEASE; PILOT PROJECTS;

EID: 0034903904     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200107000-00003     Document Type: Article

References (30)

1. A five-year study of dyskinesias in patients with early Parkinson's disease who were treated with ropinirole or levodopa
2. The dopamine transporter: A crucial component regulating dopamine transmission
3. Role of high-affinity receptors and membrane transporters in non-synaptic communication and drug action in the central nervous system
4. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals
5. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate
6. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician
7. Development and validation of a geriatric depression screening scale
8. Scales for the assessment of movement disorders
9. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases
10. Short- and long-duration response to levodopa during the first year of levodopa therapy
11. Cognitive slowing in Parkinson's and Alzheimer's patients: Distinguishing bradyphrenia from dementia
12. Executive function in Parkinson's disease: Set-shifting or set-maintenance?
13. Pharmacologically induced changes in normal arousal: Effects on behavioral and electrophysiologic measures of alertness and attention
14. Neural systems control of spatial orienting
15. Attention deficit in Alzheimer's disease is not simulated by an anticholinergic/antihistaminergic drug and is distinct from deficits in healthy aging
16. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability
17. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations
18. The clinical dementia rating (CDR): Current version and scoring roles
19. Analgesic action of methylphenidate on parkinsonian sensory symptoms: Mechanisms and pathophysiologic implications
20. Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: Possible role of the 'hedonic' dopamine synapse
21. Amphetamines: A valuable adjunct in the treatment of parkinsonism
22. Amphetamines in the treatment of Parkinson's disease
23. Methylphenidate in parkinsonism
24. Parkinsonian patients report blunted subjective effects of methylphenidate
25. Attention deficits in Parkinson's disease: Partial reversibility with naphtozazine (SDZ NVI-085), a selective noradrenergic alpha-1 agonist
26. Reduction of noradrenalin impairs attention and dopamine depletion slows responses in Parkinson's disease
27. A meta-analysis on cognitive slowing in Parkinson's disease: Are simple and choice reaction times differentially impaired?
28. New dopaminergic neurons in Parkinson's disease striatum
29. Effect of basal ganglia injury on central dopaminergic activity in gulf war syndrome